IVA Key Statistics, Chart & Performance
The current stock price of IVA is 6.055 USD. In the past month the price increased by 13.73%. In the past year, price increased by 138.44%.
IVA Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to IVA. When comparing the yearly performance of all stocks, IVA is one of the better performing stocks in the market, outperforming 97.24% of all stocks.
IVA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to IVA. IVA may be in some trouble as it scores bad on both profitability and health.
IVA Financial Highlights
Over the last trailing twelve months IVA reported a non-GAAP Earnings per Share(EPS) of -2.42. The EPS decreased by -74.11% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -173.72% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
IVA Forecast & Estimates
14 analysts have analysed IVA and the average price target is 16.79 USD. This implies a price increase of 177.26% is expected in the next year compared to the current price of 6.055.
For the next year, analysts expect an EPS growth of 45.26% and a revenue growth 1.86% for IVA
IVA Ownership
IVA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.38 | 387.092B | ||
| AMGN | AMGEN INC | 16.7 | 198.053B | ||
| GILD | GILEAD SCIENCES INC | 16.98 | 185.32B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.12 | 116.409B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.85 | 80.573B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 46.13 | 43.76B | ||
| INSM | INSMED INC | N/A | 32.21B | ||
| NTRA | NATERA INC | N/A | 27.199B | ||
| BIIB | BIOGEN INC | 12.62 | 27.192B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.57 | 20.623B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About IVA
Company Profile
Inventiva SA is a clinical-stage biopharmaceutical company, which focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis, or NASH, and other diseases with significant unmet medical need. The company is headquartered in Daix, Occitanie and currently employs 84 full-time employees. The company went IPO on 2017-02-15. The firm focuses on the development of therapies in the area of oncology, fibrosis and rare diseases. The Company’s pipeline comprises a number of development programs, such as Clinical Pipeline, Preclinical Pipeline, AbbVie Collaboration and Boehringer-Ingelheim collaboration. Its drug candidates target at the treatment of non-alcoholic steatohepatitis (NASH), systemic sclerosis (SSc), various types of mucopolysaccharidosis (MPS), multiple myeloma, auto-immune disorders, as well as lung cancer, among others. In addition, the Company offers drug discovery services, ranging from target identification to preclinical nomination, in numerous areas, such as silico modelling, biology, screening, absorption, distribution, metabolism and excretion (ADME), pharmacology and histology.
Company Info
INVENTIVA SA - ADR
50 rue de Dijon, Daix
Daix OCCITANIE 21121 FR
CEO: Frederic Cren
Employees: 84
Phone: 33380447500
INVENTIVA SA - ADR / IVA FAQ
What does INVENTIVA SA - ADR do?
Inventiva SA is a clinical-stage biopharmaceutical company, which focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis, or NASH, and other diseases with significant unmet medical need. The company is headquartered in Daix, Occitanie and currently employs 84 full-time employees. The company went IPO on 2017-02-15. The firm focuses on the development of therapies in the area of oncology, fibrosis and rare diseases. The Company’s pipeline comprises a number of development programs, such as Clinical Pipeline, Preclinical Pipeline, AbbVie Collaboration and Boehringer-Ingelheim collaboration. Its drug candidates target at the treatment of non-alcoholic steatohepatitis (NASH), systemic sclerosis (SSc), various types of mucopolysaccharidosis (MPS), multiple myeloma, auto-immune disorders, as well as lung cancer, among others. In addition, the Company offers drug discovery services, ranging from target identification to preclinical nomination, in numerous areas, such as silico modelling, biology, screening, absorption, distribution, metabolism and excretion (ADME), pharmacology and histology.
What is the current price of IVA stock?
The current stock price of IVA is 6.055 USD. The price increased by 4.4% in the last trading session.
Does INVENTIVA SA - ADR pay dividends?
IVA does not pay a dividend.
How is the ChartMill rating for INVENTIVA SA - ADR?
IVA has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the expected growth for IVA stock?
The Revenue of INVENTIVA SA - ADR (IVA) is expected to grow by 1.86% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the short interest for IVA stock?
The outstanding short interest for INVENTIVA SA - ADR (IVA) is 0.1% of its float.